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Scarcity of mutations detected in families with
In addition, both exons were analysed in 65 new unrelated subjects, including 21 females who were either obligate carriers or had manifestations of the disorder. The EDA gene was completely sequenced on a sample of people who showed no SSCP changes, to rule out the presence of a common mutation not detectable by the SSCP methodology used.
Methods

PATIENTS AND FAMILIES
A total of 183 affected subjects from unrelated families was analysed; 118 of them, all males, had been previously analysed by SSCP analysis for variants in exon 1 alone or by Southern analysis for large genomic deletions.9 10 These patients were reanalysed for mutations within exon 2. Sixty-five additional unrelated subjects, 44 males and 21 females, were analysed for mutations in both exons. Affected members of these families were clinically characterised from medical records and pedigrees provided primarily by clinicians from the US and the UK. All subjects who participated provided consent through an IRB approved protocol. There was a total of 162 males and 21 females in the study. Males had typical features of X linked hypohidrotic ectodermal dysplasia, including hypodontia, hypotrichosis, and hypohidrosis.' Females were either obligate carriers or had significant manifestations of the disorder. In families with both affected males and obligate or manifesting females, males were selected for study when possible. Fortyone of the families had been previously studied as part of earlier linkage studies and data were consistent with linkage to the Xql2-ql3. Primers for exon 2 were designed from the flanking genomic sequence. PCR was performed in a 20 ji volume with a final concentration of 1 x PCR buffer (Perkin Elmer), 3 mmoMl MgCl,, 0.2 mmol/l dNTP, 0.5 mmol/l forward primer (5'-TGGCTTCTCTAGTTAGGTTG GG-3'), 0.5 mmol/l reverse primer (5'-CA TCTCAAATTTTCCTTCTGGG-3'), 1 unit Taq DNA polymerase (Perkin Elmer), and 50 ng genomic DNA. Reactions were heated to 95°C for two minutes 30 seconds, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds, with a final extension step at 72°C for five minutes. The PCR product was 372 bp. A total of 5 pl of the PCR product was digested in a final volume of 10 ,ul with 5 U of Tru9I, generating fragments of 84, 151, and 157 base pairs.
Digests of the PCR products were denatured at 95°C for 10 mintes, chilled on ice, and electrophoresed on a 0.5 x Hydrolink MDE gel al T Baker Inc) at 1 watt/cm for three hours at room temperature. For samples analysed in the US, the DNA was stained by immersing the gel in 0.1% silver nitrate for 10 minutes, washing briefly in water, then soaking the gel in a solution of 1.5% sodium hydroxide, 0.01% sodium borohydride, and 0.15% formaldehyde. For the samples analysed in the UK, DNA from the gel was visualised by transfer onto a nylon membrane with subsequent hybridisation to radiolabelled exon 1 or 2 PCR products. The 686 bp PCR product, encompassing all of exons 1 and 35 and 51 bp of flanking sequence, was amplified from patients with abnormally migrating SSCP bands. This same product and one including 372 bp of exon 2 (32 and 38 bp of flanking sequence) were amplified from 10 subjects without any detectable changes. The complete DNA sequence was obtained from both exons, using a combination of flanking primers (see above) and internal primers (5'-GGTGACTGGTGATGGGGCTGTC-3' and 5'-AGTTGCGCTCGGAGTTG-3'). Sequencing was performed using ABI end terminator chemistry on a 373A automated sequencer. To determine if any variants detected represent polymorphisms, allele specific oligonucleotide (ASO) hybridisation was performed. 13 Seventeen base oligomers designed to detect each of the variant sequences identified within the US patient cohort, as well as the corresponding wild type sequences, were hybridised against a panel of 100 X chromosomes from unaffected subjects. Variants identified among the UK patients were examined by SSCP analysis of a panel of 70 normal X chromosomes.
Results
Seven subjects were identified with variants within exon 1 among the 65 new families studied. No SSCP variants were identified within exon 2, in either the 1 18 affected subjects from our previous study or among the new families. Sequencing of exon 1 and its flanking regions from genomic DNA of the subjects with SSCP variants identified sequence changes in all of the subjects (table 1). Two of the variants were the result of single base pair changes in the 5' untranslated region (UTR) (228G-A, 1 87G-*T). The 228G-.A variant generates an in frame ATG start codon five amino acids upstream of the anticipated start of the EDA protein. However, this alternate start site lacks the Kozak sequence seen flanking the predicted start methionine. The 228G--A variant was also detected in one unaffected control in this study, as well as in the original genomic clone containing exon 1 of the EDA gene. These data suggest that 228G-'yA is a non-disease causing polymorphism. The 187G-*T variant is not anticipated to alter the protein sequence, but might have an effect on gene expression. However, ASO hybridisation to genomic DNA from 50 control females detected one with the 187G--T variant. This suggests that it also is not a causative mutation, but rather a polymorphic variant occurring with a low frequency in the population. The 187G-T variant was detected in a previously published EDA family, in whom no other changes were detected.9 Five variants were felt to be plausible disease causing mutations (table 1) . A nonsense mutation (366C--T) in ED1 180 is predicted to truncate the protein at residue 23. A missense mutation in the amino-terminal hydrophilic region of the EDA protein is predicted by one variant (429G--A) and changes a negatively charged amino acid (glutamic acid) to a positively charged one (lysine). Three variants (427delT, 494delT, 594-5del) were detected and predict frameshift mutations at residues 62, 85, and 118, respectively. The 494delT variant had been identified previously in two families.9 Haplotype analysis of the three families with 494delT, using polymorphic markers that closely flank the EDA locus,'2 indicate that this deletion arose independently in each family (data not shown). The 594-595delCC has an associated base change, 593A--.G, which alone would be a silent mutation. All five putative mutations identified in the study were not detected among the panels of unaffected subjects.
Genomic DNA from 10 affected males with normal SSCP results was sequenced for both exons 1 and 2, including the flanking genomic regions, but no sequence variants were identified. No phenotypic differences were evident between subjects with or without identifiable mutations. In addition, there were no phenotypic differences between the subject with a putative missense mutation, the four subjects with either frameshift or nonsense mutations, or the four previously published males with However, the most likely possibility is that the majority of the EDA mutations reside in exons not represented in the original cDNA clone. Previous northern analysis using exon 1 as a probe on various fetal and adult tissues indicated RNA species of 6.0 kb, 4.5 kb, 2.0 kb, and < 1 kb.9 If the 6 kb form of the transcript is critical for normal development, then the 0.8 kb cDNA analysed would represent only 13% of the gene. Identification of alternatively spliced products, and their DNA sequences, should increase the yield of mutations detected by direct analysis. For the present, direct mutation analysis is not a practical diagnostic tool and indirect linkage based analysis must still be relied upon. Depending on the ultimate improvement in the rate of mutation detection, direct mutation analysis may replace linkage analysis, or the two techniques may be used in combination depending on the individual situation.
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